Hydroxyurea (NSC-32065)

For research use only.

Catalog No.S1896 Synonyms: NCI-C04831, Hydroxycarbamide

21 publications

Hydroxyurea (NSC-32065) Chemical Structure

CAS No. 127-07-1

Hydroxyurea (NSC-32065, NCI-C04831, Hydroxycarbamide) is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxyurea activates apoptosis and autophagy. Hydroxyurea is used to treat HIV infection.

Selleck's Hydroxyurea (NSC-32065) has been cited by 21 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Hydroxyurea (NSC-32065, NCI-C04831, Hydroxycarbamide) is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxyurea activates apoptosis and autophagy. Hydroxyurea is used to treat HIV infection.
Targets
ribonucleoside diphosphate reductase [1]
In vitro

hydroxyurea can inhibit HIV-1 replication. In vitro experiments have shown that the 90% inhibitory concentration (IC90) of hydroxyurea for laboratory strains of HIV-1 in activated PBMC is 0.4 mM. Hydroxyurea was also found to be synergistic with the nucleoside reverse transcriptase inhibitor didanosine and to inhibit HIV-1 replication in activated PBMC; this inhibition may be due to a reduction in deoxynucleoside triphosphate pool sizes. Hydroxyurea has been shown to sensitize didanosine-resistant mutants[1][2].hydroxyurea has demonstrated activity in the treatment of sickle cell anemia by increasing the production of fetal hemoglobin, which reduces hemolysis in patients with this disease. Hydroxyurea exerts its cytostatic effect through inhibition of ribonucleotide reductase—the rate-limiting enzyme responsible for the conversion of ribonucleotides to deoxyribonucleotides, which are essential for DNA synthesis. As a result, cellular division is arrested in the S phase[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
L1210 Leukemia cells NYTo[pA3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUfDc45k\W62cnH0bY9vKHKncYXpdoVlKG[xcjC1NEUhcW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEApVDF{MUCgUIV2c2WvaXGpMEBKSzVyPUKxMlM4QTZizszN MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTlzNUKwK|4zQTlzNUKwQE9iRg>?
P388 leukemic cell MUTQdo9tcW[ncnH0bY9vKGG|c3H5 NVH6[3pFOjRvNEigbC=> NWrwPZZISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhd2ZiY3;tdI92dmRiZYjwdoV{e2WmIHHzJINwdmOnboTyZZRqd25idHjheEBqdmirYnn0d{A2OCVib3[g[5Jwf3SqIH;mJHA{QDhibHX1b4VucWNiY3XscEB{fXOyZX7zbY9vKG[{b32gNlQhfG9iNEigbJIh[W[2ZYKgZ49ueG:3bnSgZYRlcXSrb36sJGlEPTB;M{Kg{txO NETSTnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C5N|czLz5{N{C5N|czRC:jPh?=
L1210 NYrMUJNxTnWwY4Tpc44h[XO|YYm= MVm0PEBp NXv5UWlKSWO2aY\peJkh[WejaX7zeEBkfWy2dYLl[EBNOTJzMDDs[ZVs\W2rYzDj[YxteyC5YYOg[IV1\XKvaX7l[EBqdiC4aYTyc{wh[W[2ZYKgOFghcCCxZjDpcoN2[mG2aX;uMkBEd22yb4Xu[EBld3OnIIToZZQh[2G3c3XzJFE3KCViaX7obYJqfGmxbjD3ZZMhemWyb4L0[YQtKEmGMU[gQUAyNjl7IN88UU4> NViwTFU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxNkOxPVcxOid-NkOxPVcxOjxxYU6=
U373-MAGI MWDGeY5kfGmxbjDhd5NigQ>? NY\uZ49{PTByIIXN NHLNTY0zKGi{cx?= MWjQc5RmdnSrYYTpc44hd2ZiNT3BfoEuSy2rbnT1Z4VlKGGwdHn2bZJidCCjY4Tpeol1gSCjZ3HpcpN1KF[VVj3HJJB{\XWmb4T5dIVlKEiLVj2xJG5NPC1|IHnu[oVkfGWmIHnuJIh2dWGwIGWzO|MuVUGJSTDj[YxteyCjc4Pld5Nm\CCjczC1MWF7[S2FIFXDOVAh[XRiNUCwJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhPS2DenGtR{Bi\GSrdHnvckBnd3JiMjDodpMh[W6mIIP1ZpNmeXWnboSgeolz[WxiaX7m[YN1cW:wIH3lZZMtKEWFNUCgQUAzPS56IN88UU4> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{K2NEc,OjdzMUeyOlA9N2F-
Burkitt's lymphoma cells NYeyVIdOTnWwY4Tpc44h[XO|YYm= NIn4b5JKdmirYnn0bY9vKG:oIGuxOGNeNWO7dHnkbY5mKGmwY3;ydI9z[XSrb36gbY51dyCGTlGgbY4hSnW{a3n0eEd{KGy7bYDoc41iKGOnbHzzMEBKSzVyIE2gN|cvOTVizszNMi=> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTRyNU[1N{c,OTF2MEW2OVM9N2F-
U373-MAGI M37LS2FvfGm4aYLhcEBie3OjeR?= MXS1NFAhfU1? NHLHPWdCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBXW1ZvRzDwd4V2\G:2eYDl[EBJUVZvMTDOUFQuOyCrbn\lZ5Rm\CCrbjDoeY1idiCXM{ezMW1CT0liY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJJZqemGuIHnu[oVkfGm4aYT5JIF1KDVyMDD1UUBqdmO3YnH0[YQh\m:{IESgbJJ{KHC{aX;yJJRwKH[rcnHsJIlv\mWldHnvckBu\WG|dYLl[EBifCB5MjDodpMheG:|dDDpcoZm[3Srb36gZpkh\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nz MnL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=
U373-MAGI NXy3d5VbTnWwY4Tpc44h[XO|YYm= NVvh[5hjOC53IH3N Mn76NkBpenN? MonhTY5kemWjc3WgbY4hPS2jenGt[GNVWC:mQ2TQJJJifGmxIHnuJIh2dWGwIGWzO|MuVUGJSTDj[YxteyCjdDCwMlUhdU1icILlbY5kfWKjdHXkJIZweiB{IHjyd{Bnd2yub4fl[EBjgSB3LXH6ZU1EKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFQhcHK|IHL5JGxENU2VL13TJIFv[Wy7c3nzJJJmdGG2aY\lJJRwKDVvYYrhMWM> M2DZZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO|I3ODxxYU6=
U373-MAGI MY\GeY5kfGmxbjDhd5NigQ>? Mk\yNkBuVQ>? NFzBXGQ3KGi{cx?= M3TlRnJm\HWldHnvckBqdiCmQWTQJIxmfmWuIHnuJIh2dWGwIGWzO|MuVUGJSTDj[YxteyCjdDCyJI1OKGGodHXyJFYhcHK|IHL5JGxENU2VL13TJIFv[Wy7c3nz NVTwc5N3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVczPjBpPkK3NVE4OjZyPD;hQi=>
U373-MAGI MYLGeY5kfGmxbjDhd5NigQ>? MVewMlUhdU1? MlPuNkBpenN? MVnS[YR2[3Srb36gbY4h\EOWUDDs[ZZmdCCrbjDoeY1idiCXM{ezMW1CT0liY3XscJMh[XRiMD61JI1OKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhPS2jenGtR{Bi\GSrdHnvckBu\WG|dYLl[EBi\nSncjC0JIhzeyCkeTDMR{1OWy:PUzDhcoFtgXOrcx?= NHq1WHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO|I3OCd-MkexNVczPjB:L3G+
U373-MAGI MUXGeY5kfGmxbjDhd5NigQ>? MlXzNkBuVQ>? M{jSU|IhcHK| M{X4cHJm\HWldHnvckBqdiCmQ2TQJIxmfmWuIHnuJIh2dWGwIGWzO|MuVUGJSTDj[YxteyCjdDCyJI1OKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhPS2jenGtR{Bi\GSrdHnvckBu\WG|dYLl[EBi\nSncjC0JIhzeyCkeTDMR{1OWy:PUzDhcoFtgXOrczDy[YxifGm4ZTD0c{A2NWG8YT3D M3i4ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO|I3ODxxYU6=
U373-MAGI MnTISpVv[3Srb36gZZN{[Xl? NHTldHcxNjVibV2= NV;2dpRUOiCqcoO= MUDJcoNz\WG|ZTDpckA2NWG8YT3kR3RRN2SFVGCgdoF1cW9iaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG2IECuOUBuVSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KDVvYYrhMYREKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFQhcHK|IHL5JGxENU2VL13TJIFv[Wy7c3nzJJJmdGG2aY\lJJRwKDVvYYrhMYRE MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{K2NEc,OjdzMUeyOlA9N2F-
U373-MAGI NFO3RYZHfW6ldHnvckBie3OjeR?= NGToWlgzKG2P MmT5NkBpenN? MY\JcoNz\WG|ZTDpckA2NWG8YT3kR3RRN2SFVGCgdoF1cW9iaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG2IEKgcW0heHKnaX7jeYJifGWmIH\vdkAzKGi{czDmc4xtd3enZDDifUA2NWG8YT3kR{Bi\GSrdHnvckBu\WG|dYLl[EBi\nSncjC0JIhzeyCkeTDMR{1OWy:PUzDhcoFtgXOrczDy[YxifGm4ZTD0c{A2NWG8YT3kRy=> MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{K2NEc,OjdzMUeyOlA9N2F-
U373-MAGI M374XmZ2dmO2aX;uJIF{e2G7 Ml7hNE42KG2P M1r4dFIhcHK| MojCVoVlfWO2aX;uJIlvKGSFVGCgcIV3\WxiaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG2IECuOUBuVSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KDVvYYrhMYREKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFQhcHK|IHL5JGxENU2VL13TJIFv[Wy7c3nzJJJmdGG2aY\lJJRwKDVvYYrhMYRE MmPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=
U373-MAGI MXzGeY5kfGmxbjDhd5NigQ>? M{nHZlIhdU1? Mmj0NkBpenN? NHW1cWVT\WS3Y4Tpc44hcW5iZFPUVEBt\X[nbDDpckBpfW2jbjDVN|c{NU2DR1mgZ4VtdHNiYYSgNkBuVSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KDVvYYrhMYREKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFQhcHK|IHL5JGxENU2VL13TJIFv[Wy7c3nzJJJmdGG2aY\lJJRwKDVvYYrhMYRE NFLYSoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO|I3OCd-MkexNVczPjB:L3G+
TC32 NVy1bHREeUiWUzDhd5NigQ>? MoXzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN? MnT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 MUDxTHRUKGG|c3H5 NVT0dZRseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= NE\EU209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 MVXxTHRUKGG|c3H5 MVXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| NVzEZ|l6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 MonrdWhVWyCjc4PhfS=> M4TFR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD MlPhdWhVWyCjc4PhfS=> MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> M3nkVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 MVXxTHRUKGG|c3H5 NGfBdpdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= NFvXZ4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) MXvxTHRUKGG|c3H5 NGnxdnJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO= NW\kSIVRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 MYTxTHRUKGG|c3H5 MmS4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= NIn6N3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 MnrBdWhVWyCjc4PhfS=> MVzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? NYDqZlMzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 MnTGdWhVWyCjc4PhfS=> Mlz0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k> NYHqd3pYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS M1PsfZFJXFNiYYPzZZk> MW\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDVMVIhV1NiY3XscJM> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 NHz5RpFyUFSVIHHzd4F6 MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MWPxTHRUKGG|c3H5 NUe1fol1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> MoLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 MV3xTHRUKGG|c3H5 NFvuSIJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=> NHu3WZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
TC32 NUG4WINbeUiWUzDhd5NigQ>? MmPVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=> NGHN[nA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[3]
- Collapse
  • Cell lines: Erythroid cells
  • Concentrations: 30 μM
  • Incubation Time: 96 h
  • Method: Erythroid cells obtained from peripheral blood of the same patients(Thirteen β-Thal/HbE patients are treated with hydroxyurea orally for 2 years at a starting dose of 5 mg/kg/day for 5 days/week with escalation to a maximum of 10 mg/kg/day) 1 year after they had stopped hydroxyurea treatment are treated with hydroxyurea in vitro.Treatment of cells performs in primary culture with 30 μM hydroxyurea for 96 hours.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: Female athymic (nu/nu) nude mice(used for xenograft model)
  • Dosages: 1500 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (197.23 mM)
Water 15 mg/mL (197.23 mM)
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 76.05
Formula

CH4N2O2

CAS No. 127-07-1
Storage powder
in solvent
Synonyms NCI-C04831, Hydroxycarbamide
Smiles C(=O)(N)NO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04808778 Recruiting Drug: Hydroxyurea therapy per standard care Sickle Cell Disease|Sickle Cell Anemia|Stroke Ischemic|Silent Stroke|Silent Cerebral Infarct|Stroke Vanderbilt University Medical Center|Aminu Kano Teaching Hospital May 17 2021 --
NCT04750707 Recruiting Drug: Hydroxyurea Sickle Cell Anemia in Children Global Health Uganda LTD|Columbia University|University of Pittsburgh|Emory University|Mulago Hospital Uganda|Makerere University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) March 9 2021 Phase 3
NCT04691323 Recruiting Other: HU-Go app Sickle Cell Disease|Sickle B+ Thalassemia|Sickle Beta Zero Thalassemia|Sickle Cell Hemoglobin C Ann & Robert H Lurie Children''s Hospital of Chicago|National Heart Lung and Blood Institute (NHLBI) March 2 2021 Not Applicable
NCT04688411 Recruiting Behavioral: MED-Go App Sickle Cell Disease|Sickle Beta Zero Thalassemia|Sickle B+ Thalassemia|Sickle Cell Hemoglobin C Ann & Robert H Lurie Children''s Hospital of Chicago|National Heart Lung and Blood Institute (NHLBI) September 28 2020 Not Applicable
NCT04093986 Recruiting Other: Chart Review|Other: Survey Sickle Cell Disease|Sickle Cell Anemia Children''s Hospital Medical Center Cincinnati|University of Connecticut|University of Colorado Denver|Guy''s and St Thomas'' NHS Foundation Trust|Duke University|Children''s Hospital of Philadelphia December 22 2019 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Hydroxyurea (NSC-32065) | Hydroxyurea (NSC-32065) supplier | purchase Hydroxyurea (NSC-32065) | Hydroxyurea (NSC-32065) cost | Hydroxyurea (NSC-32065) manufacturer | order Hydroxyurea (NSC-32065) | Hydroxyurea (NSC-32065) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID